The Purgo Pouch is a preclinical combination product, with clinical testing planned in 2026. Statements made are based on preclinical studies, which have been conducted in over 140 sheep.

How The Purgo Pouch Technology Works

Surgical Site Infection

By the Numbers in the U.S.

Surgical Site Infections Cost the U.S. Healthcare System

$10 BILLION ANNUALLY

And Impact Over 300,000 Patients a Year

#1

Cause of Healthcare Acquired Infections

9,000

Number of U.S. Patients that Die From SSI Annually

#1

Cause of Readmissions After Surgery

9.7

Average Number of Days in Hospital Due to SSI

Surgical Site Infection

By the Numbers in the U.S.

Surgical Site Infections Cost the U.S. Healthcare System

$10 BILLION ANNUALLY

And Impact Over 300,000 Patients a Year

#1

Cause of Healthcare Acquired Infections

9,000

Number of U.S. Patients that Die From SSI Annually

#1

Cause of Readmissions After Surgery

9.7

Average Number of Days in Hospital Due to SSI

The Solution

The Right Therapy

Purgo Pouch will deliver an effective tobramycin dose to kill biofilms.

The Right Place

Purgo Pouch targets infection by delivering tobramycin locally in the surgical wound site.

The Right Duration

Purgo Pouch sustains tobramycin delivery for up to 30 days, offering unparallelled versatility.

What Medical Professionals Are Saying

Kirt Kimball, MD

Purgo Pouch is a breakthrough medical device that will deliver controlled local antibiotics. The promise of controlled local drug delivery without systemic side effects and toxicity is transformative for the treatment and prevention of deep infection. I look forward to using it in my practice.

International College of Surgeons

“Surgical site infection is disastrous in orthopedic practice as it is difficult to rid the bone and joint of the infection.” Prevalence of Surgical Site Infection in Orthopedic Surgery: A 5-year Analysis – June 2014, International Surgery – Official Journal of the International College of Surgeons

Adam Hadhazy

“When encased in biofilms in the human body, bacteria are a thousand times less susceptible to antibiotics."

Edmiston C.E., McBain A.J., Roberts C., Leaper

"The global impact of surgical site infections is monumental and as many as 80% of these infections may involve a microbial biofilm.” Edmiston C.E., McBain A.J., Roberts C., Leaper D. (2015) Clinical and Microbiological Aspects of Biofilm-Associated Surgical Site Infections. In: Donelli G. (eds) Biofilm-based Healthcare-associated Infections. Advances in Experimental Medicine and Biology, vol 830. Springer, Cham. doi.org/10.1007/978-3-319-11038-

David L. Rotherberg, MD

The Purgo Pouch stands as a groundbreaking tool in localized antibiotic delivery, addressing deep infection treatment, prevention, and advancing the current surgical infection management. This level of control over drug delivery is a game-changer, and I am excited to see its impact in my clinical work.

Jeremy Shaw, MD

The Purgo Pouch is a breakthrough medical device that will deliver controlled local antibiotics. The promise of controlled local drug delivery without systemic side effects and toxicity is tranformative for the treatment and prevention of deep infection. I look forward to using it in my practice.

Purgo Pouch Is Superior To Current Clinical Approaches